Sage Therapeutics (SAGE) Dropped After Phase 3 Study Failed

Sage Therapeutics (SAGE) announced Tuesday morning that its Phase 3 trial of brexanolone in the treatment super-refractory status epilepticus failed to meet the primary endpoint.

from RTT - Before the Bell http://ift.tt/2wp3TTz
via IFTTT